1. In Vivo
  2. >>Innovation

Leqembi Approval Causes A Ripple Effect For Precision In Alzheimer’s

Insights From AC Immune CEO, Andrea Pfeifer

 
• By David Wild

On the heels of the FDA’s full approval of Biogen and Eisai’s Leqembi, AC Immune’s CEO is hopeful that a precision medicine approach with improved diagnosis, prevention and treatment of Alzheimer’s disease is not far down the road. With 16 clinical programs, notable partnerships and wholly owned assets, AC Immune holds a strong position to help reach that destination.

For AC Immune, Targeting Amyloid Plaques Is One Part Of A Bigger Therapeutic Strategy • Source: Shutterstock

As Biogen, Inc. and Eisai Co., Ltd. bask in the glow of the US Food and Drug Administration’s full approval of Leqembi (lecanemab-irmb), Andrea Pfeifer, CEO of Swiss biotech AC Immune SA, sees it is as the beginning of a journey toward a tailored approach that integrates precise screening, prevention and treatment. And the company, which she founded in 2003, is trying to fulfill the promise of that long-awaited day.

As she recently told sister publication Scrip, "Today we can slow Alzheimer's, and tomorrow we hope to stop or prevent...

More from Innovation

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.